| Clinical Trial Stage Projects | City of Hope, Beckman Research Institute | Evaluation and Characterization of SARS-CoV-2 Antibody in Convalescent Volunteer Plasma Donors for Potential Therapeutic Use |
$999,999 |
| Conference – The 2017 Alpha Stem Cell Clinic Annual Symposium | City of Hope, Beckman Research Institute | 2nd Annual Symposium of the CIRM Alpha Stem Cell Clinics Network
“Alpha Clinics – Making the Future a Reality for Stem Cell-Based Therapies” |
$79,287 |
| Clinical Trial Stage Projects | City of Hope, Beckman Research Institute | Evaluation of Safety and Feasibility of Cytomegalovirus-Specific, Anti-HIV Chimeric Antigen Receptor (CMV/HIV-CAR) T Cells in People with HIV |
$11,299,976 |
| Late Stage Preclinical Projects | City of Hope, Beckman Research Institute | Ex Vivo Gene Engineering of Blood Stem Cells for Enhanced Chemotherapy Efficacy in Glioblastoma Patients |
$3,684,259 |
| Alpha Stem Cell Clinics | City of Hope, Beckman Research Institute | The Innovation-Alpha Clinic for Cellular Therapies (I-ACT) – A Program for the Development and Delivery of Innovative Cell-based Treatments and Cures for Life-threatening Diseases. |
$8,456,000 |
| Strategic Partnership III Track A | City of Hope, Beckman Research Institute | A Phase I, Open-Label Study To Assess The Safety, Feasibility and Engraftment of Zinc Finger Nucleases (ZFN) CCR5 Modified Autologous CD34+ Hematopoietic Stem/Progenitor Cells (SB-728MR-HSPC) with Escalating Doses of Busulfan In HIV-1 (R5) Infected Sub… |
$5,583,438 |
| Disease Team Research I | City of Hope, Beckman Research Institute | ZINC FINGER NUCLEASE-BASED STEM CELL THERAPY FOR AIDS |
$14,536,969 |
